Navigation Links
Florida Woman Charges Life-Threatening Blood Clot Caused by Yaz Birth Control Drug According to Lieff Cabraser Heimann & Bernstein, LLP
Date:8/23/2011

NEW YORK, Aug. 23, 2011 /PRNewswire/ --

Wendy R. Fleishman of the national plaintiffs' law firm Lieff Cabraser Heimann & Bernstein, LLP announced that Tiffany Littles, 33, of Jacksonville, Florida, filed a personal injury lawsuit against Bayer Healthcare Pharmaceuticals, Inc., for severe and lasting injuries caused by Bayer's birth control drug Yaz. Littles' complaint charges that Yaz is a dangerous prescription drug sold without adequate warnings about the risk of serious injuries.

(Logo:  http://photos.prnewswire.com/prnh/20110823/SF56552LOGO)

In July 2008, Littles suffered a bilateral pulmonary emboli, cor pulmonale, and deep vein thrombosis ("DVT"), more commonly known as a blood clot. If left untreated, blood clots can break off and result in life-threatening conditions.

"I am bringing this lawsuit so that this traumatic event does not happen to anyone else," stated Littles. "I nearly died from taking this medication--the hospital even brought in a priest for me."

The complaint charges that Littles would not have been injured had Bayer properly warned patients of the dangers of using Yaz.

"The FDA's adverse event database for Yaz and Yasmin reveal a very high number of serious adverse events associated with these drugs, including strokes, heart attacks, blood clot formation, and sometimes death," commented attorney Fleishman. "Bayer failed to warn doctors and consumers, we allege, that Yaz and Yasmin pose a greater risk of serious injuries than earlier generation oral contraceptives."

The complaint was filed yesterday afternoon in the Philadelphia Court of Common Pleas.

For more information, please visit our Yaz birth control lawsuit page.

Yaz and Yasmin are registered trademarks of Bayer Schering Pharma Aktiengesellschaft and used for informational and product identification purposes only.

Source | Contact
Wendy R. Fleishman/Paulina do Amaral
Lieff Cabraser Heimann & Bernstein, LLP
212-355-9500

Media Contact
Stephen Cassidy
1-415-956-1000


'/>"/>
SOURCE Lieff Cabraser Heimann & Bernstein, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
2. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
3. Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida
4. CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial
5. St. Anthonys Hospital Offers First Ambient MRI In Florida
6. New Florida Law Allows Use of Instant Drug Tests On the Job Site
7. Access MediQuip Moves Company Headquarters to Lake Mary, Florida
8. Prescription Assistance Arrives in Jacksonville, Florida
9. Varian Medical Systems Showcases Advanced Radiotherapy and Brachytherapy Products at ACRO 2010, February 25-27, Florida, Booth No. 34-35
10. IVF FLORIDA Reproductive Associates Partners with The University of Miami School of Medicine and Jackson Memorial Health
11. Alliance Imaging Offers Mobile Positron Emission Mammography (PEM) Imaging to its Florida Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... -centric training, today announced the launch of a new research study, The Business ... skills needed to execute that strategy, and the actual success of achieving individual ...
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
(Date:3/27/2017)... ... 2017 , ... Golden Triangle Emergency Center will be hosting ... to commemorate the two-year anniversary of the facility. The event will feature refreshments ... years while also familiarizing themselves with the facility. , In the two years ...
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
Breaking Medicine News(10 mins):